SRZN · Surrozen, Inc.
AI read · Good for SRZN
The AI's read
The extra cash gives Surrozen more time to develop its drug candidates without needing another raise soon. It does not show whether those treatments will work in patients.
Surrozen raised $95.1 million, with the money expected to fund its work through 2029. This gives it more time to develop its treatments, though it does not show they will succeed.
The extra cash gives Surrozen more time to develop its drug candidates without needing another raise soon. It does not show whether those treatments will work in patients.
Follow Surrozen, Inc. (SRZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SRZN